Trial reportRespiratory research2012
Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease.
Trial report in Respiratory research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 35 citations in OpenAlex.
- Calprotectin Is a Circulating Biomarker and Potential Therapeutic Target for Sarcopenia in Chronic Obstructive Pulmonary Disease.Journal of cachexia, sarcopenia and muscle · 2026Article
- Culturally targeted messaging and racial equity in SARS-CoV-2 antibody testing by multiplex salivary measurement: Protocol overview of a SeroNet investigation.Brain, behavior, & immunity - health · 2025Article
- Development and validation of a prospective study to predict the risk of readmission within 365 days of respiratory failure: based on a random survival forest algorithm combined with COX regression modeling.BMC pulmonary medicine · 2024Article
- The Molecular Blueprint for Chronic Obstructive Pulmonary Disease (COPD): A New Paradigm for Diagnosis and Therapeutics.Oxidative medicine and cellular longevity · 2023Review
- Biomarker-based clustering of patients with chronic obstructive pulmonary disease.ERJ open research · 2023Article
- Airway Disease in Rheumatoid Arthritis.Annals of the American Thoracic Society · 2022Review
- Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD.International journal of molecular sciences · 2021Article
- Progress in the mechanism and targeted drug therapy for COPD.Signal transduction and targeted therapy · 2020Review
- Transcriptome-Guided Drug Repositioning.Pharmaceutics · 2019Article
- Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.Pharmacology & therapeutics · 2019Review
- Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease.Experimental and therapeutic medicine · 2018Article
- Insulin-Like Growth Factor-1 Signaling in Lung Development and Inflammatory Lung Diseases.BioMed research international · 2018Review
- Involvement of c-Jun N-Terminal Kinase in TNF-α-Driven Remodeling.American journal of respiratory cell and molecular biology · 2017Article
- Emerging pharmaceutical therapies for COPD.International journal of chronic obstructive pulmonary disease · 2017Review
- Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema.Frontiers in physiology · 2015Article
- Stage-dependent association of BDNF and TGF-β1 with lung function in stable COPD.Respiratory research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic obstructive pulmonary disease (COPD) is characterized by progressive worsening of airflow limitation associated with abnormally inflamed airways in older smokers. Despite correlative evidence for a role for tumor necrosis factor-alpha in the pathogenesis of COPD, the anti-tumor necrosis factor-alpha, infliximab did not show clinical efficacy in a double-blind, placebo-controlled, phase II clinical trial. This study sought to evaluate the systemic inflammatory profile associated with COPD and to assess the impact of tumor necrosis factor neutralization on systemic inflammation.
methodsSerum samples (n = 234) from the phase II trial were collected at baseline and after 24 weeks of placebo or infliximab. Additionally, baseline serum samples were obtained from an independent COPD cohort (n = 160) and 2 healthy control cohorts (n = 50; n = 109). Serum concentrations of a broad panel of inflammation-associated analytes were measured using a 92-analyte multiplex assay.
resultsTwenty-five proteins were significantly elevated and 2 were decreased in COPD, including highly elevated CD40 ligand, brain-derived neurotrophic factor, epidermal growth factor, acute-phase proteins, and neutrophil-associated proteins. This profile was largely independent of smoking status, age, and clinical phenotype. The majority of these associations of serum analytes with COPD are novel findings. Increased serum creatine kinase-muscle/brain and myoglobin correlated modestly with decreased forced expiratory volume at 1 second, suggesting cardiac involvement. Infliximab did not affect this systemic inflammatory profile.
conclusionsA robust systemic inflammatory profile was associated with COPD. This profile was generally independent of disease severity. Because anti-tumor necrosis factor-alpha did not influence systemic inflammation, how to control the underlying pathology beyond symptom suppression remains unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.